Medtronic announced today that it has obtained approval from China's National Medical Products Administration (NMPA) for its Symplicity Spyral™ renal denervation (RDN) system, a breakthrough in addressing hypertension in the country.
This approval marks a significant milestone as Symplicity Spyral becomes the first RDN system to gain NMPA approval in China.
This achievement in China follows recent approvals from the U.S. FDA and launches in India and Canada, underscoring Medtronic's dedication to global accessibility of this technology.
By This System blood pressure procedure is a minimally invasive technique delivering radiofrequency energy to calm overactive nerves near the kidneys, thereby reducing elevated blood pressure.
It involves the insertion of a catheter into the kidney artery, administering energy to regulate nerve activity, and leaving no implant behind.
The Symplicity Spyral system has been endorsed under the Greater Bay Area policy, allowing commercial sales to hospitals in the region.
The urgency of innovative solutions in addressing rising hypertension rates in China. The Symplicity procedure offers a promising option alongside traditional treatments, backed by substantial data demonstrating its effectiveness and safety.
Studies have shown that even modest reductions in blood pressure significantly decrease cardiovascular risk.
With a track record of over 25,000 patients globally, the system has consistently demonstrated notable reductions in blood pressure with minimal adverse events, offering improved control over hypertension over time.
Medtronic's approval of the Symplicity Spyral system in China signifies a significant step forward in combating hypertension, potentially benefiting millions by providing a safe and effective alternative treatment option.
Source: https://news.medtronic.com/Medtronic-receives-approval-for-Symplicity-Spyral-TM-Renal-Denervation-System-in-China
